Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.74 |
| ▸ | RORA | P35398 | 7/20 | 0.74 |
| ▸ | RORB | Q92753 | 2/20 | 0.74 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19556832 | 0.89 | RORC (0.80) | RORCRORARORBNR1H3NR1H2 | |
| SCHEMBL2489597 | 0.85 | RORA (1.00) | RORCRORARORBNR1H3NR1H2 | |
| SCHEMBL18588564 | 0.75 | RORA (0.82) | RORCRORARORBSMN1; SMN2 | |
| SCHEMBL12334251 | 0.72 | RORC (0.61) | RORCRORARORBNR1H3NR1H2 | |
| SCHEMBL12334255 | 0.70 | RORC (0.62) | RORCRORARORBNR1H3NR1H2 | |
| SCHEMBL12334081 | 0.68 | MCL1 (0.61) | RORCRORARORBNR1H3NR1H2 | |
| SCHEMBL11412249 | 0.67 | RORA (0.63) | RORCRORARORBNR1H3NR1H2 | |
| SCHEMBL12334260 | 0.67 | RORC (0.57) | RORCRORARORBNR1H3NR1H2 | |
| SCHEMBL2944332 | 0.67 | NR1H3 (0.66) | RORCRORARORBNR1H3NR1H2 | |
| SCHEMBL3817824 | 0.66 | RORA (0.68) | RORCRORARORBNR1H3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189858-B2 | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same | DEUTERX, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180118758-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-PIPERIDINONYL CONJUGATES AND OXOQUINAZOLIN-3(4H)-YL-PIPERIDINONYL CONJUGATES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9809603-B1 | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same | DEUTERX, LLC (US) | 2017-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189858-B2 | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same | EGLN3, AQP3, AQP4 | RORC 735/4885RORA 1472/4885RORB 1557/4885 |
| US-20180118758-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-PIPERIDINONYL CONJUGATES AND OXOQUINAZOLIN-3(4H)-YL-PIPERIDINONYL CONJUGATES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | EGLN3, AQP3, AQP4 | RORC 735/4885RORA 1472/4885RORB 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.